Why the study?
What is the clinical pharmacology, efficacy, and safety profile of ethinylestradiol 20 mcg plus levonorgestrel 100 mcg in women?
What is the clinical pharmacology, efficacy, and safety profile of ethinylestradiol 20 mcg plus levonorgestrel 100 mcg in women?
The low-dose estroprogestin combination of ethinylestradiol 20 mcg plus levonorgestrel 100 mcg offers a favorable clinical profile with effective cycle control, minimal metabolic effects, and low VTE risk.
No takes yet. Share an insight, caveat, or question.
May support EE20/LNG100 selection for cycle control with low VTE risk; leaves open need for head-to-head RCTs.
Lello et al. (2014) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: